Belimumab

B Lymphocyte Stimulator-specific Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Belimumab is a drug in the B Lymphocyte Stimulator-specific Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2011. Its mechanism of action is classified as B Lymphocyte Stimulator-directed Antibody Interactions. DrugCentral lists 1 molecular target, including TNFSF13B. Recorded indications include Systemic lupus erythematosus.

• Drug class: B Lymphocyte Stimulator-specific Inhibitor.
• Mechanism of action: B Lymphocyte Stimulator-directed Antibody Interactions.
• Molecular targets: TNFSF13B (1 listed in DrugCentral).
• Indications: Systemic lupus erythematosus.
• ATC code: L04AG04 (Monoclonal antibodies).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Systemic lupus erythematosus

Mechanism & targets

• Mechanism of action (MoA): B Lymphocyte Stimulator-directed Antibody Interactions
• Established pharmacologic class: B Lymphocyte Stimulator-specific Inhibitor

Molecular targets (1)

Target	Gene	Action	Activity
Tumor necrosis factor ligand superfamily member 13B	TNFSF13B	other	—

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2017-09-27	PMDA	—	GlaxoSmithKline KK
2011-07-13	EMA	—	Glaxo Group Ltd.
2011-03-09	FDA	—	HUMAN GENOME SCIENCES INC.

ATC classification

ATC code	Therapeutic hierarchy
L04AG04	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Monoclonal antibodies

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: TNFSF13B
• FDA label: TNFSF13B
• HCSC label: TNFSF13B

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Product dose omission issue	1460.0
Lupus nephritis	798.5
Product complaint	629.6
Wrong technique in device usage process	461.9
Therapy interrupted	384.4
SLE arthritis	301.4
Proteinuria	220.2
COVID-19	216.9
Exposure via skin contact	207.5
Therapy cessation	203.1
Product storage error	182.8
Inappropriate schedule of product administration	154.8

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 356547-88-1
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Belimumab used for?

DrugCentral lists the following indications for Belimumab: Systemic lupus erythematosus.

How does Belimumab work?

Belimumab is classified as B Lymphocyte Stimulator-directed Antibody Interactions; its molecular targets in DrugCentral include TNFSF13B.

When was Belimumab first approved?

Belimumab was first approved by the FDA in 2011.

What drug class does Belimumab belong to?

Belimumab is in the B Lymphocyte Stimulator-specific Inhibitor class.

Sources

• DrugCentral drug card 4949 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1789843 — compound record and bioactivity
• DrugBank DB08879 — drug record
• FDA UNII 73B0K5S26A — substance identity
• DailyMed: FDA labels for Belimumab — current prescribing information (label search)
• UniProt Q9Y275 (TNFSF13B) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.